Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
11
04
2023
accepted:
01
12
2023
revised:
18
11
2023
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
7
2
2024
Statut:
aheadofprint
Résumé
No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively. Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval. Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer. UMIN000007925.
Sections du résumé
BACKGROUND
BACKGROUND
No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer.
METHODS
METHODS
A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively.
RESULTS
RESULTS
Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P < 0.03) and 12 months (P < 0.001) were independent prognostic factors for a shorter recurrence-free interval.
CONCLUSIONS
CONCLUSIONS
Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer.
CLINICAL TRIAL REGISTRATION
BACKGROUND
UMIN000007925.
Identifiants
pubmed: 38326601
doi: 10.1038/s41416-023-02540-3
pii: 10.1038/s41416-023-02540-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin. Oncol. 2011;29:4387–93.
doi: 10.1200/JCO.2011.36.5908
pubmed: 22010012
Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.
doi: 10.1200/JCO.18.01138
pubmed: 30925125
pmcid: 6524985
Irino T, Matsuda S, Wada N, Kawakubo H, Kitagawa Y. Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. Ann Gastroenterol Surg. 2021;5:162–72.
doi: 10.1002/ags3.12438
pubmed: 33860136
pmcid: 8034698
Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.
doi: 10.1097/01.sla.0000152019.14741.97
pubmed: 15650634
pmcid: 1356909
Makino T, Fujiwara Y, Takiguchi S, Miyata H, Yamasaki M, Nakajima K, et al. The utility of pre-operative peritoneal lavage examination in serosa-invading gastric cancer patients. Surgery. 2010;148:96–102.
doi: 10.1016/j.surg.2009.11.025
pubmed: 20096433
Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ. Performance of 18F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients. Ann Nucl Med. 2014;28:789–95.
doi: 10.1007/s12149-014-0871-4
pubmed: 24965850
Motoori M, Takemasa I, Doki Y, Saito S, Miyata H, Takiguchi S, et al. Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site. Eur J Cancer. 2006;42:1897–903.
doi: 10.1016/j.ejca.2006.04.007
pubmed: 16831544
Otsu H, Nambara S, Hu Q, Hisamatsu Y, Toshima T, Takeishi K, et al. Identification of serum microRNAs as potential diagnostic biomarkers for detecting precancerous lesions of gastric cancer. Ann Gastroenterol Surg. 2023;7:63–70.
doi: 10.1002/ags3.12610
pubmed: 36643367
Wada N, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, et al. The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases. Surg Today. 2017;47:227–32.
doi: 10.1007/s00595-016-1408-3
pubmed: 27566604
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142–5.
doi: 10.1007/s10120-003-0240-9
pubmed: 14520526
Osayi SN, Bloomston M, Schmidt CM, Ellison EC, Muscarella P. Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review. Biomed Res Int. 2014;2014:468959.
Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–8.
doi: 10.1073/pnas.94.5.1914
pubmed: 9050879
pmcid: 20017
Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001;92:856–60.
doi: 10.1002/ijc.1282
pubmed: 11351307
Jäger E, Srockert E, Zidianakis Z, Cnen YT, Karbach J, Jäger D, et al. Humoral immune responses of cancer patients against ‘cancer-testis’ antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 1999;84:506–10.
doi: 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6
pubmed: 10502728
Hoshino I, Nabeya Y, Takiguchi N, Gunji H, Ishige F, Iwatate Y, et al. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. Ann Gastroenterol Surg. 2020;4:275–82.
doi: 10.1002/ags3.12325
pubmed: 32490341
pmcid: 7240143
Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187:1349–54.
doi: 10.1084/jem.187.8.1349
pubmed: 9547346
pmcid: 2212223
Türeci Ö, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett. 2006;236:64–71.
doi: 10.1016/j.canlet.2005.05.008
pubmed: 15992994
Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res. 2004;10:6551–8.
doi: 10.1158/1078-0432.CCR-04-0819
pubmed: 15475443
Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108:1119–25.
doi: 10.1038/bjc.2013.51
pubmed: 23403818
pmcid: 3619069
Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268–86.
doi: 10.1101/gad.190678.112
pubmed: 22713868
pmcid: 3387655
Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25:161–8.
doi: 10.1038/cdd.2017.185
pubmed: 29099488
Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.
doi: 10.1002/cncr.11092
pubmed: 12548611
Shimada H. P53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2018;2:266–73.
doi: 10.1002/ags3.12179
pubmed: 30003189
pmcid: 6036386
Takahashi R, Sakamoto K, Sugimoto K, Motegi S, Tsukamoto R, Ichikawa R, et al. Significance of serum p53 antibody as a tumor marker in colorectal cancer. Dis Markers. 2019;2019:2721876.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016;20:1–19.
doi: 10.1007/s10120-016-0622-4
pmcid: 5215069
Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5:1124–31.
doi: 10.1001/jamaoncol.2019.0528
pubmed: 31070691
pmcid: 6512280
Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer supplemental content. JAMA Oncol. 2019;5:1710–7.
doi: 10.1001/jamaoncol.2019.3616
pubmed: 31621801
pmcid: 6802034
Nakamura Y, Fujisawa T, Taniguchi H, Bando H, Okamoto W, Tsuchihara K, et al. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: path to the realization of biomarker-guided precision oncology in advanced solid tumors. Cancer Sci. 2021;112:4425–32.
doi: 10.1111/cas.15132
pubmed: 34510657
pmcid: 8586659
Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915–20.
doi: 10.1111/cas.14926
pubmed: 33931919
pmcid: 8253296
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26:1859–64.
doi: 10.1038/s41591-020-1063-5
pubmed: 33020649
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25:4255–63.
doi: 10.1158/1078-0432.CCR-18-3663
pubmed: 30992300
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432–7.
doi: 10.1038/s41586-021-03642-9
pubmed: 34135506
Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11:525.
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New Engl J Med. 2022;2261–72 https://doi.org/10.1056/nejmoa2200075 .
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 2023;29:127–34.
Collier AY, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. New Engl J Med. 2021;385:2008–9.
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. New Engl J Med. 2021;385:e84.
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–25.
doi: 10.1093/epirev/mxj009
pubmed: 16754644
Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494–508.e5.
doi: 10.1016/j.ccell.2021.01.003
pubmed: 33545063
pmcid: 8044023
Guo G, Yu M, Xiao W, Celis E, Cui Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 2017;77:2292–305.
doi: 10.1158/0008-5472.CAN-16-2832
pubmed: 28280037
pmcid: 5465961
Francis DM, Manspeaker MP, Schudel A, Sestito LF, O’Melia MJ, Kissick HT, et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020;12:1–12.
doi: 10.1126/scitranslmed.aay3575
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.
doi: 10.1126/science.aaa1348
pubmed: 25765070
pmcid: 4993154
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Engl J Med. 2014;371:2189–99.
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 2011;108:16723–8.
doi: 10.1073/pnas.1110814108
pubmed: 21933959
pmcid: 3189057
Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, et al. Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-programmed cell death-1 therapy in NSCLC. J Thorac Oncol. 2019;14:2071–83.
doi: 10.1016/j.jtho.2019.08.008
pubmed: 31449889
Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N, et al. A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Clin Chim Acta. 2021;519:51–59.
doi: 10.1016/j.cca.2021.04.008
pubmed: 33865813